Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Promethera Biosciences and LifeLiver Sign Alliance

Written by DS on in the category news with the tags , .


Promethera Biosciences SA, the world-leading cell therapy and regenerative medicine company targeting liver diseases, and LifeLiver, the Korean leader in the field of treatment of severe liver diseases, today announced a strategic alliance to jointly develop Promethera’s suite of cell-based liver disease therapies in South Korea.

This alliance initially includes:

(a) a licence agreement for HepaStem and H2Stem to develop and commercialize these platforms in Promethera’s main indications in NASH and ACLF in Korea and

(b) a supply agreement to provide Heparesc® for LifeLiver’s proprietary bioartificial liver (BAL) system.

Promethera and LifeLiver will collaborate on the clinical development of Promethera's and LifeLiver’s product applications. Initially, LifeLiver will combine Promethera's human mature hepatocytes liver cell suspension, Heparesc®, with its proprietary bioartificial liver (BAL) system for the ex vivo treatment of patients with severe liver diseases such as Acute Liver Failure. The therapeutic goal of this approach would be to “humanize” the BAL bioreactor and to boost supply of hepatocytes. Future directions of this strategic alliance will involve other indications currently clinically investigated by Promethera such as urea cycle disorders and will include the HepaStem and H2Stem technologies.

“This alliance represents a great opportunity for Promethera to shape the global commercialization strategy for our novel cell-based therapeutics. Even more importantly, the partnership offers us a way to benefit from the positive environment for such cutting-edge therapies and regenerative medicine in Korea and to drive the development of our novel platforms in this key market,” said John Tchelingerian, CEO of Promethera Biosciences. “LifeLiver, which also participated strategically in Promethera’s Series C financing extension round, represents the ideal partner to approach the South Korean market early on given their strong position and network in their home market.”

“Combining our bio-artificial liver (BAL) system with Promethera’s current and next-generation human liver-derived cell-based therapies opens up unique future product opportunities to serve patients in Korea in an innovative way. We look forward to combining our expertise with Promethera’s to bring breakthrough cell-based ex vivo and in vivo treatment options to the Korean market,” said Ha Young Kim, CEO at LifeLiver. “Hepatocytes are among the most difficult cells to preserve for a longer time period. For this reason, having a supply agreement in place with Promethera will allow us to humanize and maintain our BAL technology in a ready-to use state for any emergent clinical situation.”

Read more about: , .

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Itera Life Science Turnstone V-Bio Ventures KU Leuven Flanders.bio UGent Biowin Janssen GSK XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.